The race to catch KRAS, pancreatic cancer’s ‘greasy ball,’ and create the most promising drug in decades

Or, how $RVMD is now worth $30B

https://
statnews.com/2026/04/19/dar
axonrasib-pancreatic-cancer-kras-revolution-medicines-patient-story/
… via
@angRchen
#AACR26